||PLX647 is a highly selective dual FMS/KIT kinase inhibitor (IC50: 28/16 nM).
||AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
||Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed un
||GW2580 is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.
||CC-223 is an orally available mTOR inhibitor with potential antitumor activity. CC-223 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and
||PF-477736 is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
||Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. A
||cFMS Receptor Inhibitor II
||cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor
||Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451/217 nM), respecti
||AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM).
||Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 14
||Nampt-IN-1 (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.
||PLX5622 hemifumarate is a highly selective brain penetrant and oral active inhibitor of CSF1R(Ki of 5.9 nM).
||CSF1R-IN-1 is a CSF1R inhibitor with IC50 of 0.5 nM.
||c-Fms-IN-2 is an inhibitor of FMS kinase (IC50: 0.024 μM).
||c-Fms-IN-6 is a potent inhibitor of c-FMS (IC50 ≤10 nM for unphosphorylated c-FMS) and also weakly inhibits unphosphorylated c-KIT and PDGFR (IC50: > 1 μM).
||c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1 (Example 7). It inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT (IC50s: <0.01 μM and 0.1-1 μM).
||K-80003 is a potent inhibitor of cancer cell growth and tRXRα-dependent Akt activation.